News

NASDAQ: ABVC

Press Releases

ABVC’s Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million

 ABVC’s Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million 150 150 Press Release
  • Press Release

FREMONT, CA – April 3, 2025 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced that its majority-owned subsidiary, AiBtl BioPharma Inc., has signed a strategic share-based land acquisition agreement with local landholders in central Taiwan. The transaction, valued at $7,666,667, involved the exchange of AiBtl shares priced at $5.00[1] per share and secured exclusive rights to agricultural land for future pharmaceutical production. The acquired land will be designated for the cultivation and extraction of Polygala tenuifolia (Yuan Zhi), a central ingredient in AiBtl’s botanical drug candidates for Major…

ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential

 ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential 150 150 Press Release

FREMONT, CA – March 19, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, provides an update on its cash milestone payment receivables per global licensing agreements and $60 million CDMO acquisition, reinforcing its strategic positioning for long-term growth. With three major global licensing agreements across psychiatric disorders, ophthalmic medical devices, and oncology, coupled with a fully integrated pharmaceutical manufacturing facility, we believe that ABVC is well-positioned to generate revenue and expand its commercial footprint. $19 Million in Global Licensing Agreements Securing Future Cash Revenue Since 2023,…

𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝘄𝗼 𝗪𝗼𝗿𝗹𝗱𝘀: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗔𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗮𝗻𝗱 𝗦𝘁𝘂𝗱𝗲𝗻𝘁𝘀 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗶𝗻𝗴 𝗧𝗮𝗶𝘄𝗮𝗻

 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝘄𝗼 𝗪𝗼𝗿𝗹𝗱𝘀: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗔𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗮𝗻𝗱 𝗦𝘁𝘂𝗱𝗲𝗻𝘁𝘀 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗶𝗻𝗴 𝗧𝗮𝗶𝘄𝗮𝗻 1068 783 ABVC

As someone who moved to Taiwan over 14 years ago to pursue higher studies and later transitioned into a fulfilling career, I’m proud to represent the growing community of Indians working and living in Taiwan. My journey here has been one of learning, adaptation, and immense professional growth, and I’m keen to share insights with aspirants back in India who are considering Taiwan as a destination for education and work. 𝗪𝗵𝘆 𝗧𝗮𝗶𝘄𝗮𝗻? Taiwan offers a unique combination of high-quality education, advanced research opportunities, and a thriving job market. With its world-class universities and cutting-edge industries, it’s an ideal place for…

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

 ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones 150 150 Press Release

ABVC BioPharma, Inc. Reports Q3 ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in income Received Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024 FREMONT, Calif., Nov. 14, 2024 — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the third quarter ended September 30, 2024. Key Financial and Operational Highlights:…

2024 ABVC Investor Presentation

View the latest product information, status updates, financial information, and more.

VIEW PRESENTATION
PRESS RELEASES
SEC FILINGS
INVESTOR CONSIDERATIONS
CONTACT ABVC
SAFE HARBOR STATEMENT

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Investor Considerations

  • Strong portfolio of medicines and medical devices addresses wide range of disorders.
  • In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
  • MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
  • Botanical expertise leads to medicines with fewer side effects.
  • Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
  • Business model designed to minimize burn rate.
  • Less than 30 million shares outstanding.

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.